Neoplasms of the Adrenal and Endocrine Pancreas in the Elderly

  • Christopher P. Coppola
  • Ronald C. Merrell


With the variety of functions served by the adrenal glands and their deep location inaccessible to direct physical examination, it is no surprise that the management of adrenal neoplasm is a fascinating and challenging venture. An age-dependent increase in both malignant adrenal disease and concomitant medical disease, further complicates treatment decisions in elderly patients. Because nearly every type of adrenal tumor occurs more frequently in women, women over the age of 64 represent a disproportionate share of patients with adrenal tumors. Some patients seek medical attention secondary to symptoms caused by abnormal adrenal secretion. Adrenocortical tissue can produce excess mineralocor-ticoids, glucocorticoids, or sex steroids; and medullary tissue can overproduce catecholamines.


Vasoactive Intestinal Peptide Multiple Endocrine Neoplasia Type Primary Aldosteronism Adrenal Mass Laparoscopic Adrenalectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    US Bureau of the Census: Population Projections. Government Printing Office: Washington, DC, 1993.Google Scholar
  2. 2.
    Glazer HS, Weyman PJ, Sagel SS, et al. Nonfunctioning adrenal masses: incidental discovery on computed tomography. AJR 1982;139:81–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Newsome HH. Adrenal glands. In: Greenfield LJ, Mulholland MW, Oldham KT, et al. (eds) Surgery: Scientific Principles and Practice. Lippincott: Philadelphia, 1993: 1209–1224.Google Scholar
  4. 4.
    Carpenter PC. Cushing’s syndrome: update of diagnosis and management. Mayo Clin Proc 1986;61:49–58.PubMedCrossRefGoogle Scholar
  5. 5.
    Tsagarakis S, Grossman A. The hypothalamic-pituitary-adrenal axis in senescence. In: Morley JE, Dorenman SG (eds) Endocrinology and Metabolism in the Elderly. Black-well Scientific: Boston, 1992:70–93.Google Scholar
  6. 6.
    Morley JE. Hormones, aging, and endocrine disorders in the elderly. In: Felig P, Baxter JD, Frohman LA (eds) Endocrinology and Metabolism, 3rd ed. McGraw-Hill: New York, 1995:1813.Google Scholar
  7. 7.
    MacLennan WJ, Peden NR. Pituitary and adrenal disorders. In: MacLennan WJ, Peden NR (eds) Metabolic and Endocrine Problems in the Elderly. Springer: Berlin, 1989: 124–135.CrossRefGoogle Scholar
  8. 8.
    Merrell RC. Aldosterone-producing tumors (Conn’s syndrome). Semin Surg Oncol 1990;6:66–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Herrera MF, Grant CS, van Heerden JA, et al. Incidentally discovered adrenal tumors: an institutional perspective. Surgery 1991:110:1014–1021.PubMedGoogle Scholar
  10. 10.
    Lucon AM, Pereira MAA, Mendonça BB, et al. Pheochro-mocytoma: study of 50 cases. J Urol 1997;157:1208–1212.PubMedCrossRefGoogle Scholar
  11. 11.
    Van Heerden JA, Young WF Jr, Grant CS, Carpenter PC. Adrenal surgery for hypercortisolism—surgical aspects. Surgery 1995;117:466–472.PubMedCrossRefGoogle Scholar
  12. 12.
    Han M, Burnett AL, Fishman EK, et al. The natural history and treatment of adrenal myelolipoma. J Urol 1997;157: 1213–1216.PubMedCrossRefGoogle Scholar
  13. 13.
    Linos DA, Stylopoulos N, Boukis M, et al. Anterior, posterior, or laparoscopic approach for the management of adrenal diseases? Am J Surg 1997;173:120–125.PubMedCrossRefGoogle Scholar
  14. 14.
    Proye CAG, Huart JY, Cuvillier XD, et al. Safety of the posterior approach in adrenal surgery: experience in 105 cases. Surgery 1993;114:1126–1131.PubMedGoogle Scholar
  15. 15.
    Lo CY, van Heerden JA, Grant CS, Söreide JA, Warner MA, Ilstrup DM. Adrenal surgery in the elderly: too risky? World J Surg 1996;20:368–374.PubMedCrossRefGoogle Scholar
  16. 16.
    Doherty GM, Nieman LK, Cutler GB Jr, et al. Time to recovery of the hypothalamic-pituitary-adrenal axis after curative resection of adrenal tumors in patients with Cushing’s syndrome. Surgery 1990;108:1085–1090.PubMedGoogle Scholar
  17. 17.
    Brunicardi FC, Rosman PM, Lesser KL, et al. Current status of adrenalectomy for Cushing’s disease. Surgery 1985; 98:1127–1133.PubMedGoogle Scholar
  18. 18.
    Sjöberg HE, Blombäck M, Granberg PO. Thromboembolic complications, heparin treatment and increase in coagulation factors in Cushing’s syndrome. Acta Med Scand 1976;199:95–98.PubMedCrossRefGoogle Scholar
  19. 19.
    Obara T, Ito Y, Okamoto T, et al. Risk factors associated with postoperative persistent hypertension in patients with primary aldosteronism. Surgery 1992;112:987–993.PubMedGoogle Scholar
  20. 20.
    Peplinski GR, Norton JA. The predictive value of diagnostic tests for pheochromocytoma. Surgery 1994;116:1101–1110.PubMedGoogle Scholar
  21. 21.
    Sutton MG St J, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma: review of a 50-year autopsy series. Mayo Clin Proc 1981;56:354–360.Google Scholar
  22. 22.
    Samaan NA, Hickey RC, Shutts PE. Diagnosis, localization, and management of pheochromocytoma: pitfalls and follow-up in 41 patients. Cancer 1988;62:2451–2460.PubMedCrossRefGoogle Scholar
  23. 23.
    Terzolo M, Ali A, Osella G, et al. Prevalence of adrenal carcinoma among incidentally discovered adrenal masses: a retrospective study from 1989 to 1994. Arch Surg 1997;132: 914–919.PubMedCrossRefGoogle Scholar
  24. 24.
    Henley DJ, van Heerden JA, Grant CS, et al. Adrenal cortical carcinoma: a continuing challenge. Surgery 1983;94:926–931.PubMedGoogle Scholar
  25. 25.
    Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992;112:963–971.PubMedGoogle Scholar
  26. 26.
    Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195–1201.PubMedCrossRefGoogle Scholar
  27. 27.
    Dieckmann K-P, Hamm B, Pickartz H, et al. Adrenal myelolipoma: clinical, radiologic, and histologic features. Urology 1987;29:1–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Cushing H. The baasophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932;50:137–195.Google Scholar
  29. 29.
    Roth GS, Livingston JN. Reductions in glucocorticoid inhibition of glucose oxidation and presumptive glucocorticoid receptor content in rat adipocytes during aging. Endocrinology 1976;99:831–839.PubMedCrossRefGoogle Scholar
  30. 30.
    Orth DN. Cushing’s syndrome. N Engl J Med 1995;332: 791–803.PubMedCrossRefGoogle Scholar
  31. 31.
    Rosenbaum AH, Schatzberg NF, MacLaughlin RA, et al. The dexamethasone suppression test in normal control subjects: comparison of two assays and effect of age. Am J Psychiatry 1984;141:1550–1555.PubMedGoogle Scholar
  32. 32.
    Avgerinos PC, Yanovski JA, Oldfield EH, Nieman LK, Cutler GB Jr. The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison. Ann Intern Med 1994;121:318–327.PubMedCrossRefGoogle Scholar
  33. 33.
    Schteingart DE. The diagnosis and medical management of Cushing’s syndrome. In: Thompson NW, Vinik AW (eds) Endocrine Surgery Update. Grune & Stratton: Orlando, 1983:87.Google Scholar
  34. 34.
    Neville AM, O’Hare MJ. Aspects of structure, function and pathology. In: James VHT (ed) The Adrenal Gland. Raven: New York, 1979:1–66.Google Scholar
  35. 35.
    Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981;71:855–875.PubMedCrossRefGoogle Scholar
  36. 36.
    Salassa RM, Laws ER, Carpenter PC, et al. Cushing’s disease: 50 years later. Trans Am Clin Climatol Assoc 1982;94:122–129.Google Scholar
  37. 37.
    Valimaki M, Pelkonen R, Porkka L, et al. Long-term results of adrenal surgery in patients with Cushing’s syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf) 1984;20:229–236.CrossRefGoogle Scholar
  38. 38.
    Prinz RA. A comparison of laparoscopic and open adrenalectomies. Arch Surg 1995;130:489–494.PubMedCrossRefGoogle Scholar
  39. 39.
    McLeod MK. Complications following adrenal surgery. J Natl Med Assoc 1990;83:161–164.Google Scholar
  40. 40.
    Malmaeus J, Markæs A, Oberg K, et al. Adrenal gland surgery: preoperative location of lesions, histologic findings and outcome of surgery. Acta Chir Scand 1986;152: 577–581.PubMedGoogle Scholar
  41. 41.
    Grabner P, Jauer-Jensen M, Jervell J, et al. Long-term results of treatment of Cushing’s disease by adrenalectomy. Eur J Surg 1991;157:461–464.PubMedGoogle Scholar
  42. 42.
    Blichert-Toft M, Bagerskov A, Lockwood K, et al. Operative treatment, surgical approach, and related complications in 195 operations upon the adrenal gland. Surg Gynecol Obstet 1972;135:261–266.PubMedGoogle Scholar
  43. 43.
    Sarkar R, Thompson NW, McLeod MK. The role of adrenalectomy in Cushing’s syndrome. Surgery 1990;108:1079–1084.PubMedGoogle Scholar
  44. 44.
    Zeiger MA, Fraker DL, Pass HI, et al. Effective reversibility of the signs and symptoms of hypercortisolism by bilateral adrenalectomy. Surgery 1993;114;1138–1134.PubMedGoogle Scholar
  45. 45.
    Lacroix A, Bolté E, Tremblay J, et al. Gastric inhibitory polypeptide-dependent Cortisol hypersecretion: a new cause of Cushing’s syndrome. N Engl J Med 1992;327; 974–980.PubMedCrossRefGoogle Scholar
  46. 46.
    Reznik Y, Allali-Zerah V, Chayvialle JA, et al. Food-dependent Cushing’s syndrome mediated by aberrantadrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992;327:98–99.CrossRefGoogle Scholar
  47. 47.
    Priestley JT, Sprague RG, Walters W, Salassa RM. Subtotal adrenalectomy for Cushing’s syndrome: a preliminary report of 29 cases. Ann Surg 1951;134:464–472.PubMedGoogle Scholar
  48. 48.
    Bennett AH, Cain JP, Dluhy RG, Tynes WV, Harrison JH, Thorn GW. Surgical treatment of adrenocortical hyper-plasas: 20-year experience. J Urol 1973;109:321–324.PubMedGoogle Scholar
  49. 49.
    O’Riordain DS, Farley DR, Young WF Jr, Grant CS, van Heerden JA. Long-term outcome of bilateral adrenalectomy in patients with Cushing’s syndrome. Surgery 1994;116:1088–1094.PubMedGoogle Scholar
  50. 50.
    Young WF Jr, Hogan MJ, Klee GG, et al. Primary aldosteronism: diagnosis and management. Mayo Clin Proc 1990;65:96–110.PubMedCrossRefGoogle Scholar
  51. 51.
    Dunnick NR, Leight GS Jr, Roubidoux MA, et al. CT in the diagnosis of primary aldosteronism: sensitivity in 29 patients. Am J Radiol 1993;160:321–324.Google Scholar
  52. 52.
    Melby JC. Diagnosis of hyperaldosteronism. Endocrinol Metab Clin North Am 1991;20:247–255.PubMedGoogle Scholar
  53. 53.
    Nakada T, Kubota Y, Sasagawa I, et al. Therapeutic outcome of primary aldosteronism: adrenalectomy versus enucleation of aldosterone-producing adenoma. J Urol 1995;153:1775–1780.PubMedCrossRefGoogle Scholar
  54. 54.
    Schenker Y. Medical treatment of low-renin aldosteronism. Endocrinol Metab Clin North Am 1989;18:415–442.Google Scholar
  55. 55.
    . Meikle AW, Daynes RA, Araneo BA. Adrenal androgen secretion and biologic effects. Endocrinol Metab Clin North Am 1991;20:381–400.PubMedGoogle Scholar
  56. 56.
    Gabrilove JL, Seman AT, Sabet R, et al. Virilizing adrenal adenoma with studies. 1981;2:462–470.Google Scholar
  57. 57.
    . Gabrilove JL, Sharma DC, Wotiz HH, Dorfman RI. Feminizing adrenocoartical tumors in the male: a review of 52 cases including a case report. Medicine 1965;44:37–79.PubMedCrossRefGoogle Scholar
  58. 58.
    Cryer PE. Phaeochromocytoma. Clin Endocrinol Metab 1985;14:203–220.PubMedCrossRefGoogle Scholar
  59. 59.
    Sheps SG, Jiang N-S, Klee GG. Diagnostic evaluation of pheochromocytoma. Endocrinol Metab Clin North Am 1988;17:397–414.PubMedGoogle Scholar
  60. 60.
    Van Heerden JA, Sheps SG, Hamberger B, et al. Pheochromocytoma: current status and changing trends. Surgery 1982;91:367–373.PubMedGoogle Scholar
  61. 61.
    Bastounis E A, Karayiannakis AJ, Anapliotou MLG, et al. Incidentalomas of the adrenal gland: diagnostic and therapeutic implications. Am Surg 1997;63:356–360.PubMedGoogle Scholar
  62. 62.
    Canee WG, Wells SA Jr. Multiple endocrine neoplasia type IIa. Curr Probi Surg 1985;22:7–56.Google Scholar
  63. 63.
    Richard S, Beigelman C, Duclos J-M, et al. Pheochromocytoma as the first manifestation of von Hippel-Lindau disease. Surgery 1994;116:10076–10081.Google Scholar
  64. 64.
    Khosla S, Patel VM, Hay ID, et al. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J Clin Invest 1991;87:1691–1699.PubMedCrossRefGoogle Scholar
  65. 65.
    Pick L. Das ganglioma embryonale sympathicum, eine typische bosartige geschwuestform des sympathischen nerven systems. Berl Klin Wochenschr 1912;49:16–22.Google Scholar
  66. 66.
    Olson JA Jr, Wells SA Jr. In: Sabiston DC Jr, Lyerly HK, (eds). Textbook of Surgery the Biological Basis of Modern Surgical Practice, 15th ed. Saunders, Philadelphia, 1997:694, with permission.Google Scholar
  67. 67.
    Zuckerkandl E. Ueber neben organe des sympathicus in retroperitonaealraum des menschen. Anat Anz 1901;15:97.Google Scholar
  68. 68.
    Altergott R, Barbato A, Lawrence A, et al. Spectrum of cat-echolamine-secreting tumors of the organ of Zuckerkandl. Surgery 1985;98:1121–1126.PubMedGoogle Scholar
  69. 69.
    Remine WH, Chong GC, van Heerden JA, et al. Current management of pheochromocytoma. Ann Surg 1974;179: 740–748.PubMedCrossRefGoogle Scholar
  70. 70.
    Orchard T, Grant CS, van Heerden JA, et al. Pheochromocytoma: continuing evolution of surgical therapy Surgery 1993;114:1153–1159.PubMedGoogle Scholar
  71. 71.
    Gifford RW Jr, Manger WM, Bravo EL. Pheochromocytoma. Endocrinol Metab Clin North Am 1994;23:387–404.PubMedGoogle Scholar
  72. 72.
    Bravo EL, Gifford RW Jr. Pheochromocytoma. Endocrinol Metab Clin North Am 1993;22:329–341.PubMedGoogle Scholar
  73. 73.
    Shapiro B, Fig LM. Management of pheochromocytoma. Endocrinol Metab Clin North Am 1989;18: 443–481.PubMedGoogle Scholar
  74. 74.
    Abecassis M, McLoughlin MJ, Langer B, et al. Serendipitous adrenal masses: prevalence, significance and management. Am J Surg 1985;149:783–788.PubMedCrossRefGoogle Scholar
  75. 75.
    . Hedeland H, Östberg G, Hökfelt B. On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Med Scand 1968; 184:211–214.PubMedCrossRefGoogle Scholar
  76. 76.
    Kokko JP, Brown TC, Berman MM. Adrenal adenoma and hypertension. Lancet 1967;1:468–470.PubMedCrossRefGoogle Scholar
  77. 77.
    . Russi S, Blumenthal HT. Small adenomas of the adrenal cortex in hypertension and diabetes. Arch Intern Med 1945;76:284–290.CrossRefGoogle Scholar
  78. 78.
    Russell RP, Mas AT, Richter ED. Adrenal cortical adenomas and hypertension: a clinical pathologic analysis of 690 cases with material controls and a review of the literature. Medicine 1972;51:211–225.PubMedCrossRefGoogle Scholar
  79. 79.
    Commons RR, Callaway CP. Adenomas of the adrenal cortex. Arch Intern Med 1948;81:37–41.CrossRefGoogle Scholar
  80. 80.
    Hensen J, Stark S, Pavel M, et al. Non-functioning adrenocortical adenomas (ACA): age and sex dependency. Presented at the 76th Annual Meeting of the Endocrine Society, June 15,1994, Anaheim, CA.Google Scholar
  81. 81.
    Copeland PM. The incidentally discovered adrenal mass. Ann Intern Med 1983;98;940–945.PubMedCrossRefGoogle Scholar
  82. 82.
    Belldegrun A, Hussain S, Seltzer SE, et al. Incidentally discovered mass of adrenal gland. Surg Gynecol Obstet 1986;163:203–208.PubMedGoogle Scholar
  83. 83.
    Gajraj H, Young AE. Adrenal incidentaloma. Br J Surg 1993:80:422–126.PubMedCrossRefGoogle Scholar
  84. 84.
    Ross NS, Aron DC. Hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med 1990;323:1401–1405.PubMedCrossRefGoogle Scholar
  85. 85.
    Bitter DA, Ross DS. Incidentally discovered adrenal masses. Am J Surg 1989;158:159–161.PubMedCrossRefGoogle Scholar
  86. 86.
    Didolkar MS, Bescher RA, Elias EG, et al. Naturai history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 1981;47:2153–2161.PubMedCrossRefGoogle Scholar
  87. 87.
    Zornoza J, Bernardino ME. Bilateral adrenal metastasis: “head light” sign. Urology 1980;15:91–92.PubMedCrossRefGoogle Scholar
  88. 88.
    Pagani JJ, Bernardino ME. Incidence and significance of serendipitous CT findings in the oncologic patient. J Comput Assist Tomogr 1982;6:268–275.PubMedCrossRefGoogle Scholar
  89. 89.
    Candel AG, Gattuso P, Reyes CV, et al. Fine-needle aspiration biopsy of adrenal masses in patients with extraadrenal malignancy. Surgery 1993;114:1132–1137.PubMedGoogle Scholar
  90. 90.
    Abeshouse GA, Goldstein RB, Abeshouse BS. Adrenal cysts: review of the literature and report of three cases. J Urol 1959;81:711–719.PubMedGoogle Scholar
  91. 91.
    Zografos GC, Driscoll DL, Karakousis CP, et al. Adrenal adenocarcinoma: a review of 53 cases. J Surg Oncol 1994;55:160–164.PubMedCrossRefGoogle Scholar
  92. 92.
    Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992;112:972–980.PubMedGoogle Scholar
  93. 93.
    Bodie B, Novick AC, Pontes JE, et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 1989; 141:257–260.PubMedGoogle Scholar
  94. 94.
    Gross MD, Shapiro B, Boufard AJ, et al. Distinguish benign from malignant euadrenal masses. Ann Intern Med 1988; 109:613–618.PubMedCrossRefGoogle Scholar
  95. 95.
    Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev 1995;16:460–484.PubMedGoogle Scholar
  96. 96.
    Schorr I, Tathnam, Saxena BB, et al. Multiple specific hormone receptors in the adenylate cyclase of an adrenocortical carcinoma. J Biol Chem 1971;246:5806–5811.PubMedGoogle Scholar
  97. 97.
    Reznek RH, Armstrong P. Imaging in endocrinology: the adrenal gland. Clin Endocrinol (Oxf) 1994;40:561–576.CrossRefGoogle Scholar
  98. 98.
    Falke THM, Sandler MO. Classification of silent adrenal masses: time to get practical. J Nucl Med 1994;35: 1152–1154.PubMedGoogle Scholar
  99. 99.
    Kvols LK, Buck M. Chemotherapy of endocrine malignancies: a review. Semin Oncol 1987;14:343–353.PubMedGoogle Scholar
  100. 100.
    Schteingart DE, Motazedi A, Noonan RA, et al. Treatment of adrenal carcinomas. Arch Surg 1982;117:1142–1146.PubMedCrossRefGoogle Scholar
  101. 101.
    Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993;71:3119–3123.PubMedCrossRefGoogle Scholar
  102. 102.
    Gierke E. Über Knochenmarksgewebe in der nebenniere. Bietr Z Pathol Anat 1905;37(suppl 7):311.Google Scholar
  103. 103.
    Oberling C. Les formations myelo-lipomateuses. Bull Assoc Fr Etude Cancer 1929;18:234.Google Scholar
  104. 104.
    Plaut A. Myelolipoma in the adrenal cortex. Am J Pathol 1958;34:487.PubMedGoogle Scholar
  105. 105.
    McDonnell WV. Myelolipomas of adrenal. Arch Pathol 1956;61:416.Google Scholar
  106. 106.
    Olsson CA, Krane RJ, Klugo RC, et al. Adrenal Myelolipoma. Surgery 1973;73:665–670.PubMedGoogle Scholar
  107. 107.
    Meaglia JP, Schmidt JD. Natural history of an adrenal myelolipoma. J Urol 1992;147:1089–1090.PubMedGoogle Scholar
  108. 108.
    Cyran KM, Kenney PJ, Memel DS, et al. Adrenal myelolipoma. AJR 1996;166:395–400.PubMedCrossRefGoogle Scholar
  109. 109.
    Oliva A, Duarte B, Hammadeh R, et al. Myelolipoma and endocrine dysfunction. Surgery 1988;103:711–715.PubMedGoogle Scholar
  110. 110.
    Filobbos SA, Seddon JA. Myelolipoma of the adrenal 1980. Br J Surg 1980;67:147–148.PubMedCrossRefGoogle Scholar
  111. 111.
    Albala DM, Chung CJ, Sueoka BL, et al. Hemorrhagic myelolipoma of adrenal gland after blunt trauma. Urology 1991;38:559–562.PubMedCrossRefGoogle Scholar
  112. 112.
    Medeiros LJ, Wolf BC. Traumatic rupture of an adrenal myelolipoma [letter]. Arch Pathol Lab Med 1983;107:500.PubMedGoogle Scholar
  113. 113.
    Mayo CW. Paroxysmal hypertension with tumor of retroperitoneal nerve. JAMA 1927;89:1047.CrossRefGoogle Scholar
  114. 114.
    Vargas HI, Davoussi LR, Bartlett DL, et al. Laparoscopic adrenalectomy: a new standard of care. Urology 1997; 49:673–678.PubMedCrossRefGoogle Scholar
  115. 115.
    Young HH. A technique for simultaneous exposure and operation on the adrenals. Surg Gynecol Obstet 1936; 54:179–188.Google Scholar
  116. 116.
    Russell CF, Hamberger B, van Heerden JA, et al. Adrenalectomy: anterior or posterior approach? Am J Surg 1982;144:322–324.PubMedCrossRefGoogle Scholar
  117. 117.
    Buell JF, Alexander HR, Norton JA, et al. Bilateral adrenalectomy for Cushing’s syndrome: anterior versus posterior surgical approach. Ann Surg 1997;225:63–68.PubMedCrossRefGoogle Scholar
  118. 118.
    Gagner M, Lacroix A, Prinz RA, et al. Early experience with laparoscopic approach for adrenalectomy. Surgery 1993; 114:1120–1125.PubMedGoogle Scholar
  119. 119.
    Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probi Surg 1994;31:79–156.Google Scholar
  120. 120.
    Kloppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Pract 1988;183:155–168.PubMedCrossRefGoogle Scholar
  121. 121.
    Larsson C, Skogseid B, Öberg K, et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85–87.PubMedCrossRefGoogle Scholar
  122. 122.
    Burke AP, Sobin LH, Shekitka KM, et al. Somatostatin-pro-ducing duodenal carcinoids in patients with von Recklinghausen’s neurofibromatosis: a predilection for black patients. Cancer 1990;65:1591–1595.PubMedCrossRefGoogle Scholar
  123. 123.
    Binkovitz LA, Johnson CD, Stephens DH. Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to multiple endocrine neoplasia. AJR 1990; 155:501–505.PubMedCrossRefGoogle Scholar
  124. 124.
    Davoren PM, Epstein MT. Insulinoma complicating tuberous sclerosis [letter]. J Neurol Neurosurg Psychiatry 1992; Y5:1209.CrossRefGoogle Scholar
  125. 125.
    Doherty GM, Doppman JL, Shawker TH, et al. Results of a prospective strategy to diagnose, localize and resect insulinoma. Surgery 1991;110:989–997.PubMedGoogle Scholar
  126. 126.
    Mozell E, Stenzel P, Woltering EA, et al. Functional endocrine tumors of the pancreas: clinical presentation, diagnosis, and treatment. Curr Probi Surg 1990:309–383.Google Scholar
  127. 127.
    Sheppard BC, Norton JA, Doppman JL, et al. Management of islet cell tumors in patients with multiple endocrine neoplasia; a prospective study. Surgery 1989;106:1108–1118.PubMedGoogle Scholar
  128. 128.
    Pasieka JL, McLeod MK, Thompson NW, et al. Surgical approach to insulinomas assessing the need for localization. Arch Surg 1992;127:442–447.PubMedCrossRefGoogle Scholar
  129. 129.
    Grunberger G, Weiner JL, Silverman R, et al. Factitious hypoglycemia due to surreptitious administration of insulin: diagnosis, treatment and long-term follow-up. Ann Intern Med 1988;188:252–257.CrossRefGoogle Scholar
  130. 130.
    Norton JA, Shawker TH, Doppman JL, et al. Localization and surgical treatment of occult insulinomas. Ann Surg 1990;212:615–620.PubMedCrossRefGoogle Scholar
  131. 131.
    Rosch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography N Engl J Med 1992;172:1721–1726.CrossRefGoogle Scholar
  132. 132.
    Doppman JL, Miller DL, Chang R, et al. Insulinomas localization with selective intraarterial injection of calcium. Radiology 1991;178:327–241.Google Scholar
  133. 133.
    Rothmund M, Angelini L, Brunt LM, et al. Surgery for benign insulinoma: an international review. World J Surg 1990;14:393–399.PubMedCrossRefGoogle Scholar
  134. 134.
    Buchanan KD, Johnston CF, O’Hare MMT, et al. Neuroendocrine tumors: a European view. Am J Med 1986;81(suppl 68):14–23.PubMedCrossRefGoogle Scholar
  135. 135.
    Eriksson B, Oberg K, Skogseid B. Neuroendocrine pancreatic tumors: clinical findings in a prospective study of 84 patients. Acta Oncol 1989;28:373–377.PubMedCrossRefGoogle Scholar
  136. 136.
    Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955;142:709–723.PubMedCrossRefGoogle Scholar
  137. 137.
    Jensen RT, Gardner JD. Zollinger-Ellison syndrome: clinical presentation, pathology, diagnosis and treatment. In: Dannenberg A, Zakim D (eds) Peptic Ulcer and Other Acid-Related Diseases. Academic Research Association: New York, 1991:117–121.Google Scholar
  138. 138.
    Delcore R, Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg 178:187–211.Google Scholar
  139. 139.
    Pipeleers-Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplastic type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990;322:723–727.PubMedCrossRefGoogle Scholar
  140. 140.
    Stabile BE, Morrow DJ, Passaro E. The gastrinoma triangle: operative implications. Am J Surg 1984;147:25–31, with permission.PubMedCrossRefGoogle Scholar
  141. 141.
    Thorn AK, Norton JA, Axotis CA, et al. Location, incidence and malignant potential of duodenal gastrinomas. Surgery 1991;110:1086–1093.Google Scholar
  142. 142.
    Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome: results of a 10 year prospective study. Ann Surg 1992;215:8–18.PubMedCrossRefGoogle Scholar
  143. 143.
    Anderson DK. Current diagnosis and management of Zollinger-Ellison Syndrome. Ann Surg 1989;210:685–703.Google Scholar
  144. 144.
    Maton PN, Frucht H, Vinayek R, et al. Medical management of patients with Zollinger-Ellison syndrome. Gastroenterology 1988;94:924–929.Google Scholar
  145. 145.
    Frucht H, Howard JM, Slaff JF. Secretin and calcium, provocative tests in patients with Zollinger-Ellison syndrome: a prospective study. Ann Intern Med 1989;111: 713–722.PubMedCrossRefGoogle Scholar
  146. 146.
    Imamura M, Takahashi K, Adachi H, et al. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg 1987;205:230–239.PubMedCrossRefGoogle Scholar
  147. 147.
    Norton JA, Cromack DT, Showker TH, et al. Intraoperative ultrasonographic localization of islet cell tumors. Ann Surg 1988;207:160–168.PubMedCrossRefGoogle Scholar
  148. 148.
    Thompson NW, Vinik AI, Eckhauser FE. Microgastrinomas of the duodenum. Ann Surg 1989;209:396–404.PubMedCrossRefGoogle Scholar
  149. 149.
    Sugg SL, Norton JA, Fraker DL, et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg 1993;218:138–144.PubMedCrossRefGoogle Scholar
  150. 150.
    Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 1958;25:374–380.PubMedCrossRefGoogle Scholar
  151. 151.
    Mekhjian HS, O’Dorisio TM. VIPoma syndrome. Semin Oncol 1987;14:282–291.PubMedGoogle Scholar
  152. 152.
    Rambaud JR, Modiglianni R, Matuchansky C, et al. Pancreatic cholera: studies on tumoral secretion and pathophysiology of diarrhea. Gastroenterology 1975;69: 110–122.PubMedGoogle Scholar
  153. 153.
    Marks IN, Bank S, Louw JH. Islet cell tumor of the pancreas with reversible watery diarrhea and achlorhydria. Gastroenterology 1967;53:695–708.Google Scholar
  154. 154.
    Verner JV, Morrison AB. Endocrine pancreatic islet disease with diarrhea: report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases. Arch Intern Med 1974;133:492–500.PubMedCrossRefGoogle Scholar
  155. 155.
    Boden G. Glucagonomas and insulinomas. Gastroenterol Clin North Am 1989;18:831–845.PubMedGoogle Scholar
  156. 156.
    Boden G, Shimoyama R. Somatostatinoma. In: Cohen S, Soloway RD (eds) Hormone-Producing Tumors of the Gastrointestinal Tract. Churchill Livingstone: New York, 1985:85.Google Scholar
  157. 157.
    Dent RB, van Heerden JA, Weiland LJ. Nonfunctioning islet cell tumors. Ann surg 1981;193:185–193.CrossRefGoogle Scholar
  158. 158.
    Broughan TA, Leslie JD, Soto JM, et al. Pancreatic islet cell tumors. Surgery 1986;99:671–678.PubMedGoogle Scholar
  159. 159.
    Weil C. Gastroenteropancreatic endocrine tumors. Klin Wochenschr 1985;63:433–459.PubMedCrossRefGoogle Scholar
  160. 160.
    Cheslyn-Curtis S, Sitaram V, Williams RCN. Management of non-functioning neuroendocrine tumours of the pancreas. Br J Surg 1993;80:625–627.PubMedCrossRefGoogle Scholar
  161. 161.
    Legaspi A, Brennan MF. Management of islet cell carcinoma. Surgery 1988;104:1018–1023.PubMedGoogle Scholar
  162. 162.
    Langstein HN, Norton JA, Chaiang HCV, et al. The utility of circulating levels of human pancreatic polypeptide as a marker of islet cell tumors. Surgery 1990;108: 1109–1116.PubMedGoogle Scholar
  163. 163.
    Dial PF, Braasch JW, Rossi, RL, et al. Management of nonfunctioning islet cell tumors of the pancreas. Surg Clin North Am 1985;65:291–299.PubMedGoogle Scholar
  164. 164.
    Eckhauser FE, Chung PS, Vinik AI, et al. Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 1986;100:978–988.PubMedGoogle Scholar
  165. 165.
    White TJ, Edney JA, Thompson JS, et al. Is there a prognostic difference between functional and nonfunctional islet cell tumors? Am J Surg 1994;168:627–630.PubMedCrossRefGoogle Scholar
  166. 166.
    Thompson GB, van Heerden JA, Grant CS, et al. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 1988;104:1011–1017.PubMedGoogle Scholar
  167. 167.
    Broder LE, Carter SK. Pancreatic islet cell carcinoma: clinical features of 52 patients. Ann Intern Med 1973;79:101–107.PubMedCrossRefGoogle Scholar
  168. 168.
    Moertel CF, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;292:941–945.Google Scholar
  169. 169.
    Blackburn AM, Bryant MG, Adrian TE, et al. Pancreatic tumors produce neurotensin. J Clin Endocrinol Metab 1981;52:820–822.PubMedCrossRefGoogle Scholar
  170. 170.
    Bostwick DG, et al. Growth hormone-releasing factor immunoreactivity in human endocrine tumors. Am J Pathol 1984;117:167–170.PubMedGoogle Scholar
  171. 171.
    Corrin B, et al. Oat cell carcinoma of the pancreas with ectopic ACTH secretion. Cancer 31:1523–1527.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Christopher P. Coppola
  • Ronald C. Merrell

There are no affiliations available

Personalised recommendations